XNASTYRA
Market cap842mUSD
Jan 14, Last price
15.94USD
1D
5.56%
1Q
-38.46%
IPO
-23.40%
Name
Tyra Biosciences Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-69m
L+33.66%
CFO
-50m
L-0.29%
Earnings
May 29, 2025
Profile
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 80,298 | 59,223 | |||
Unusual Expense (Income) | |||||
NOPBT | (80,298) | (59,223) | |||
NOPBT Margin | |||||
Operating Taxes | (3,602) | ||||
Tax Rate | |||||
NOPAT | (80,298) | (55,621) | |||
Net income | (69,134) 33.66% | (51,723) 97.86% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 1,537 | 632 | |||
BB yield | -0.26% | -0.20% | |||
| Debt | |||||
Debt current | 560 | 140 | |||
Long-term debt | 12,712 | 5,104 | |||
Deferred revenue | |||||
Other long-term liabilities | 46 | 169 | |||
Net debt | (190,197) | (246,969) | |||
| Cash flow | |||||
Cash from operating activities | (50,139) | (50,285) | |||
CAPEX | (770) | (559) | |||
Cash from investing activities | (144,605) | (559) | |||
Cash from financing activities | 1,537 | 632 | |||
FCF | (84,395) | (57,589) | |||
| Balance | |||||
Cash | 203,469 | 251,213 | |||
Long term investments | 1,000 | ||||
Excess cash | 203,469 | 252,213 | |||
Stockholders' equity | (164,445) | (95,692) | |||
Invested Capital | 375,529 | 2,787 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 42,705 | 41,884 | |||
Price | 13.85 82.24% | 7.60 -45.98% | |||
Market cap | 591,463 85.81% | 318,318 -45.41% | |||
EV | 401,266 | 71,349 | |||
EBITDA | (79,945) | (58,927) | |||
EV/EBITDA | |||||
Interest | 296 | ||||
Interest/NOPBT | |||||